Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ARCHIVE
DIAGNOSTIC NEWS IN BRIEF
Forecasts Lab Test Market to Total \347.1 Bil. in 2004: Fuji KeizaiFuji Keizai Co, Ltd published on August 5 "Laboratory Tests 2004," a lab test market survey report based on analyses of 38 major manufacturers of lab test reagents and…
To read the full story
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…